Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

Blood ◽  
2001 ◽  
Vol 97 (11) ◽  
pp. 3658-3661 ◽  
Author(s):  
Patrizia Mancuso ◽  
Alessandra Burlini ◽  
Giancarlo Pruneri ◽  
Aron Goldhirsch ◽  
Giovanni Martinelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endothelial Cells ◽  
Cancer Patients ◽  
Circulating Endothelial Cells ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Color Flow ◽  
Cell Adhesion Molecule 1 ◽  
Endothelial Growth Factor

Circulating endothelial cells (CECs) were enumerated in 20 healthy controls and 76 newly diagnosed cancer patients by means of 4-color flow cytometry. In breast cancer (n = 46) and lymphoma (n = 30) patients, both resting and activated CECs were increased by 5-fold (P < .0008 vs control). CECs significantly correlated with plasma levels of vascular cell adhesion molecule-1 and vascular endothelial growth factor. Resting and activated CECs were similar to healthy controls in 7 lymphoma patients achieving complete remission after chemotherapy, and activated CECs were found to decrease in 13 breast cancer patients evaluated before and 24 hours after quadrantectomy.

Plasma vascular endothelial growth factor level and cognitive changes in breast cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20566-e20566
Author(s):  
Terence Ng ◽  
Yin Ting Cheung ◽  
Maung Shwe Ham Guo ◽  
Yuan Chuan Kee ◽  
Han Kiat Ho ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cognitive Functioning ◽  
Cancer Patients ◽  
Response Speed ◽  
Vascular Endothelial ◽  
Breast Cancer Patients ◽  
Endothelial Growth Factor ◽  
Vegf Level

e20566 Background: It is suggested that vascular endothelial growth factor (VEGF) induces neurogenesis in the brain and provides neuroprotectiveeffects. This study was designed to examine the relation between plasma VEGF level and cognitive functioning in breast cancer patients who have received chemotherapy. Methods: Early-stage breast cancer patients (stage I to III) who received anthracycline- and/or taxane-based chemotherapy were prospectively recruited at a single center. Perceived cognitive functioning (FACT-Cog) and computerized neuropsychological assessment (Headminder) were used to evaluate patients’ cognitive function at three time points: prior to chemotherapy (T1), at midpoint (T2), and end of chemotherapy (T3). Headminder evaluated four cognitive domains: Attention, Memory, Processing, and Response speed. Impairment in each domain were defined as a >2.5 reduction of the Z score from baseline, as calculated by the reliable change index for repeated cognitive measurements. Plasma VEGF levels were analyzed at each time point using the multiplex immunoassay. Spearman Correlation (rs) was utilized to correlate the change in plasma VEGF and neurocognitive functioning. Results: Thirty-six patients were recruited (median age: 51.5; Chinese: 80.6%; post-menopausal: 58.3%). Median plasma VEGF levels were T1: 19.2 pg/ml; T2: 26.5 pg/ml; T3: 21.9 pg/ml. Weak correlations were observed between the change in VEGF level and the change in FACT-Cog and Headminder scores for individual cognitive domain (Table). Conclusions: Results suggest a weak correlation between plasma VEGF level and cognitive functioning in the domains of attention, concentration, functional interferences, mental acuity and response speed. Larger sample size and longer follow up are required to further explore the findings. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document